ORLISTAT 60cps da 120mg – DIMAGRANTE BRUCIA GRASSI – SWISS

Product Description: Orlistat

Indications:
Orlistat is primarily used for the treatment of obesity in patients with a body mass index (BMI) greater than 30 kg/m², and it may be considered for those with a BMI of 28 kg/m² or more if associated risk factors are present. The treatment should be combined with a moderately hypocaloric diet. It is essential to initiate therapy only after there has been a demonstrated weight loss of at least 2.5 kg over a period of 4 opeenvolgende weken on a diet alone. The administration of Orlistat should be terminated after 12 weken if the patient has not achieved at least 5% weight loss from their initial weight.

Pharmacological Properties:
Orlistat is a synthetic derivative of lipstatin, a natural product derived from Streptomyces toxytricini. It functions by irreversibly inhibiting gastric and pancreatic lipases, the enzymes responsible for breaking down dietary fats into free fatty acids and absorbable monoglycerides. The inhibition of these enzymes results in reduced digestion of dietary triglycerides, leading to a decrease in cholesterol absorption and solubility, as well as reduction in fat-soluble vitamin absorption. Overall, Orlistat reduces fat absorption by about 30%. For a typical 2,000 calorie diet that comprises about 30% fat as caloric content, this translates to an approximately 20g of fat excreted in the feces daily (equivalent to roughly 180 kilocalories less introduced per day). Importantly, the absorption of Orlistat itself is minimal, exerting its action strictly at the intestinal level.

Clinical Efficacy:
Due to its unique mechanism of action, Orlistat has generated significant interest as a potential long-term treatment for obesity in a therapeutic landscape lacking safe alternatives. For weight management, Fluoxetine (e.g., Prozac), an SSRI, is the only alternative approved for treating bulimia, as it plays a crucial role in appetite and weight regulation.

Clinical studies, which were concurrently double-blind and placebo-controlled, ranged from 1 to 2 years and included patients with a BMI of between 28 and 47 kg/m². Patients were selected based on a 4-5 week pre-study period on a diet to assess their motivation and adherence to the protocol. Over the span of one year, treatment with Orlistat alongside a moderately hypocaloric diet (less than 1,500 calories/day) yielded an average additional weight loss of approximately 3.5 kg compared to the placebo group. Notably, about 20.2% of the patients treated with Orlistat lost at least 10% of their initial weight, compared to 8.3% in the placebo group. In studies lasting two years, during the second year, transitioning from a hypocaloric to a normocaloric diet meant that Orlistat could not prevent weight regain. Furthermore, no specific effects were observed on obesity-related risk factors, and its efficacy in patients resistant to dietary measures remains unproven; thus, caution against using Orlistat as a substitute for dietary changes is advised.

Dosering en toediening:
The typical dosage of Orlistat is 120 mg taken orally with each main meal that contains fat, up to drie keer per dag. Consistent adherence to a reduced-calorie, low-fat diet is essential for optimal results.

Voorzichtigheid:
Before starting therapy with Orlistat, patients should discuss any existing health conditions and medications with their healthcare provider to prevent potential adverse effects. Regular follow-up appointments should be scheduled to monitor progress and manage any side effects.